, Tracking Stock Market Picks
Enter Symbol:
Medicinova, Inc. (MNOV) [hlAlert]

Mkt Outperform
down 25.56 %

Medicinova, Inc. (MNOV) rated Mkt Outperform with price target $9 by Rodman & Renshaw

Posted on: Thursday,  May 15, 2008  8:25 AM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform Medicinova, Inc. (NASDAQ: MNOV) on 05/15/2008, when the stock price was $3.99.
Since then, Medicinova, Inc. has lost 25.56% as of 08/27/2015's recent price of $2.97.
If you would have followed this Rodman & Renshaw's recommendation on MNOV, you would have lost 25.56% of your investment in 2660 days.

Medicinova, Inc., incorporated in September 2000, is a biopharmaceutical company focused on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the United States market. Through strategic alliances primarily with Japanese pharmaceutical companies, the Company is developing a portfolio of clinical and preclinical product candidates. Medicinova has acquired licenses to eight compounds for the development of 10 product candidates. Its development pipeline includes eight programs which have been in clinical development for the treatment of asthma, acute exacerbations of asthma, multiple sclerosis, or MS, interstitial cystitis (IC), solid tumor cancers, Generalized Anxiety Disorder/insomnia, preterm labor and urinary incontinence. The Company is focused on the development of two prioritized assets in its development pipeline: MN-221 for the treatment of status asthmaticus, and MN-166 for the treatment of MS.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/15/2008 8:25 AM Buy
3.99 9.00
as of 12/24/2008
1 Week down  -10.23 %
1 Month up  9.65 %
3 Months down  -8.96 %
1 YTD up  21.38 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy